CO6862110A2 - Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos - Google Patents
Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicosInfo
- Publication number
- CO6862110A2 CO6862110A2 CO14018361A CO14018361A CO6862110A2 CO 6862110 A2 CO6862110 A2 CO 6862110A2 CO 14018361 A CO14018361 A CO 14018361A CO 14018361 A CO14018361 A CO 14018361A CO 6862110 A2 CO6862110 A2 CO 6862110A2
- Authority
- CO
- Colombia
- Prior art keywords
- paclitaxel
- treatment
- combination
- gynecological cancers
- erbb3 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503342P | 2011-06-30 | 2011-06-30 | |
| US201161529630P | 2011-08-31 | 2011-08-31 | |
| FR1250860 | 2012-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6862110A2 true CO6862110A2 (es) | 2014-02-10 |
Family
ID=47424747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14018361A CO6862110A2 (es) | 2011-06-30 | 2014-01-29 | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140248280A1 (es) |
| EP (1) | EP2726100A4 (es) |
| JP (1) | JP2014527035A (es) |
| KR (1) | KR20140063578A (es) |
| CN (1) | CN103945866A (es) |
| AU (1) | AU2012275850A1 (es) |
| BR (1) | BR112013033544A2 (es) |
| CA (1) | CA2839869A1 (es) |
| CO (1) | CO6862110A2 (es) |
| EA (1) | EA201490180A1 (es) |
| MA (1) | MA35281B1 (es) |
| MX (1) | MX2013015333A (es) |
| TW (1) | TW201317002A (es) |
| UY (1) | UY34178A (es) |
| WO (1) | WO2013003037A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| PT2544680E (pt) | 2010-03-11 | 2015-05-06 | Merrimack Pharmaceuticals Inc | Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo |
| EA201500503A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| EP3169708B1 (en) * | 2014-07-16 | 2019-03-20 | Dana-Farber Cancer Institute Inc. et Al. | Her3 inhibition in low-grade serous ovarian cancers |
| JP2018513155A (ja) | 2015-04-17 | 2018-05-24 | メリマック ファーマシューティカルズ インコーポレーティッド | セリバンツマブを用いた併用療法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| MX2018011054A (es) | 2016-03-15 | 2019-01-21 | Merrimack Pharmaceuticals Inc | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073629A2 (en) * | 2006-11-03 | 2008-06-19 | Board Of Regents, The University Of Texas System | Bifunctional predictors of cancer treatment sensitivity and resistance |
| PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| PT2544680E (pt) * | 2010-03-11 | 2015-05-06 | Merrimack Pharmaceuticals Inc | Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo |
-
2012
- 2012-06-13 WO PCT/US2012/042164 patent/WO2013003037A2/en active Application Filing
- 2012-06-13 BR BR112013033544A patent/BR112013033544A2/pt not_active IP Right Cessation
- 2012-06-13 EP EP12803745.4A patent/EP2726100A4/en not_active Withdrawn
- 2012-06-13 MX MX2013015333A patent/MX2013015333A/es unknown
- 2012-06-13 CN CN201280041592.0A patent/CN103945866A/zh active Pending
- 2012-06-13 JP JP2014518607A patent/JP2014527035A/ja active Pending
- 2012-06-13 EA EA201490180A patent/EA201490180A1/ru unknown
- 2012-06-13 KR KR1020147002211A patent/KR20140063578A/ko not_active Application Discontinuation
- 2012-06-13 AU AU2012275850A patent/AU2012275850A1/en not_active Abandoned
- 2012-06-13 US US14/130,058 patent/US20140248280A1/en not_active Abandoned
- 2012-06-13 CA CA2839869A patent/CA2839869A1/en not_active Abandoned
- 2012-06-29 UY UY0001034178A patent/UY34178A/es not_active Application Discontinuation
- 2012-06-29 TW TW101123370A patent/TW201317002A/zh unknown
-
2014
- 2014-01-22 MA MA36703A patent/MA35281B1/fr unknown
- 2014-01-29 CO CO14018361A patent/CO6862110A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201317002A (zh) | 2013-05-01 |
| WO2013003037A2 (en) | 2013-01-03 |
| BR112013033544A2 (pt) | 2017-12-19 |
| CA2839869A1 (en) | 2013-01-03 |
| US20140248280A1 (en) | 2014-09-04 |
| MA35281B1 (fr) | 2014-07-03 |
| EP2726100A2 (en) | 2014-05-07 |
| CN103945866A (zh) | 2014-07-23 |
| UY34178A (es) | 2013-01-31 |
| AU2012275850A1 (en) | 2013-03-21 |
| EP2726100A4 (en) | 2015-04-29 |
| MX2013015333A (es) | 2014-07-09 |
| KR20140063578A (ko) | 2014-05-27 |
| EA201490180A1 (ru) | 2014-08-29 |
| JP2014527035A (ja) | 2014-10-09 |
| WO2013003037A3 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6821893A2 (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b | |
| CO6862110A2 (es) | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos | |
| CO7061081A2 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| CO6821964A2 (es) | Compuestos para el tratamiento de la adicción | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| DK2707030T3 (da) | Cancerbehandlinger | |
| BR112013021783A2 (pt) | sutiã para tratamento com radiação | |
| CO6801724A2 (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| EP2849785A4 (en) | METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES | |
| HK1222869A1 (zh) | 用於治療癌症的針對 的偶聯抗體 | |
| HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
| CO6821965A2 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| FR2971576B1 (fr) | Ballon eclairant | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| EP3030268A4 (en) | Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers | |
| HK1204629A1 (en) | Treatment of mucositis with immunoglobulin | |
| DK3329927T3 (da) | IBS-behandling med probiotika | |
| CO6880061A2 (es) | Método para tratar el cáncer mediante el uso combinado de fármacos | |
| IS2934B (is) | Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun | |
| BR112014028306A2 (pt) | métodos para tratamento de câncer gástrico. | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| FI20126009A (fi) | Sektoriloisto | |
| ZA201504169B (en) | Anti-adam28 antibody for treating cancer | |
| ES1076161Y (es) | Revestimiento integral para el interior de automoviles. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |